NexImmune (OTCMKTS:NEXI) & Endonovo Therapeutics (OTCMKTS:ENDVD) Head to Head Analysis

Earnings and Valuation

This table compares Endonovo Therapeutics and NexImmune”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$170,000.00	0.00	-$400,000.00	($10.00)	N/A
NexImmune	N/A	N/A	-$32.34 million	($18.29)	N/A

Endonovo Therapeutics has higher revenue and earnings than NexImmune.

Insider & Institutional Ownership

9.9% of NexImmune shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 14.9% of NexImmune shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Endonovo Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, NexImmune has a beta of -2282.12, suggesting that its stock price is 228,312% less volatile than the S&P 500.

Profitability

This table compares Endonovo Therapeutics and NexImmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%
NexImmune	N/A	N/A	N/A

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.

About NexImmune

NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.